Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pig placenta patch helps stubborn wounds heal?

NCT ID NCT07170566

Disease control Sponsor: ConvaTec Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at a wound dressing made from pig placenta, called InnovaMatrix AC, in 67 people with hard-to-heal wounds. The goal was to see if it was safe and helped wounds close. Researchers measured how much the wound shrank after 4 weeks and how long it took to fully heal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
InnovaMatrix AC (a wound dressing made from pig placenta)
What this could lead to
If successful, this could provide a safe and effective option for treating stubborn wounds that don't heal with standard care.
What could go wrong
This is a small, single-center observational study with no comparison group. Results may not apply to all patients, and the dressing may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

67 people

The number who actually took part.

Started

May 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult subjects seen at the study site between 1 May 2022 (the date of first product use according to the study site) to 27 March 2024 (the date of contract signature), who meet the inclusion and exclusion criteria. There will be no new patient visits associated with this retrospective study, therefore patient duration is not applicable.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects aged 18 years or older at the time the data were reported. * Subjects with hard-to-heal wound(s), defined as those that have failed to show improvement (which is defined as ≥50% reduction in wound area) over 4-weeks of standard wound care. * Initial Wound area that is \>0.5 cm2 and \<10 cm2 * InnovaMatrix® AC applied to target wound(s) for a minimum of two consecutive weekly visits inside a 4-week period. * Subjects were compliant with wound protection strategies through treatment period (offloading, compression, etc). * The target wound(s) is not undergoing active management at the time of data entry. Exclusion Criteria: * Wound area showed ≥50% reduction in 4-weeks preceding initial InnovaMatrix® AC application. * Cases where InnovaMatrix® AC was not applied at a minimum of two consecutive weekly visits inside a 4-week period. * Subjects who were non-compliant with additional wound protection strategies (offloading, compression, etc) * Subjects with severe comorbidities that significantly impact healing ability, or ability for subject to be compliant with wound protection strategies, such as: peripheral vascular disease (ABI \<0.4, \>1.3)1, severely uncontrolled diabetes (Hgb A1C \>9.0%), neurodegenerative disorders, Charcot foot, high dose corticosteroid or other immunosuppressant, etc * Wound area \<0.5 cm2 or \>10 cm2 * The target wound is still under active treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wound heal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Wound heal

Contacts and locations

Locations

  • Charleston Wound Care Centre

    Mt. Pleasant, South Carolina, 29464, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.